Trials / Completed
CompletedNCT05793684
AD816 Crossover Study
Phase 2 Randomized Double-Blind Placebo-Controlled Multiple-Dose 3-Period Crossover Study to Compare a Fixed Dose Combination of AD816 to Viloxazine Alone and to Placebo in Obstructive Sleep Apnea
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Apnimed · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The VicTor Study is a randomized, double blind, placebo-controlled, 3-period, multiple-dose crossover study in participants with OSA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Period A | Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo |
| DRUG | Period B | Week 1: AD816 low dose; Week 2: AD816 high dose |
| DRUG | Period C | Week 1: Placebo + Placebo; Week 2: Placebo + Placebo |
Timeline
- Start date
- 2023-04-28
- Primary completion
- 2023-11-09
- Completion
- 2023-11-09
- First posted
- 2023-03-31
- Last updated
- 2023-11-15
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05793684. Inclusion in this directory is not an endorsement.